Halberd Corp. & Mississippi State University Discuss Animal Testing as Prelude to FDA Certification

JACKSON CENTER, PA / ACCESSWIRE / June 8, 2022 / Halberd Corporation (OTC PINK:HALB) and Mississippi State University (MSU) executed a non-disclosure agreement (NDA) to explore animal testing as the next step in obtaining FDA certification for Halberd's patented extracorporeal disease eradication processes. Consistent with its press release of May 18, 2022, Halberd commenced its pursuits with mdi Consultants, Inc, an FDA application consulting firm, and the FDA to determine specific animal testing requirements. Animal testing will be planned and executed with FDA certification requirements in mind in order to most efficiently utilize available funding, R&D resources, and planned time-to-market for Halberd's technology. Halberd has already successfully completed proof-of-concept testing of its patented extra-corporeal (outside the body) disease eradication process on bacteria, inflammatory cytokines and other neurodegenerative disease antigens.

FDA related certification is the next logical step following Halberd's historic laboratory accomplishments in successfully eradicating, in vitro, select antigens associated with one or more neurodegenerative diseases, such as Alzheimer's Disese, Parkinson's Disease, Epilepsy, and other significant disease states.

Dr. Mitchell S. Felder, Halberd's Chief Technology Officer and a board-certified attending neurologist stated, "We are very pleased to have the accomplished professors at Mississippi State University assisting in this significant step in proving the efficacy of Halberd's technology. Animal testing would further validate Halberd's exciting technology and help in ultimately obtaining FDA approval for effective treatment of these devastatingly debilitating diseases which have plagued mankind for millennia."

William A. Hartman, Chairman, President & CEO of Halberd Corporation, added, "We are anxious to begin substantive technical discussions with experts in animal testing which can simulate our technology's impact on the treatment and potential eradication of these terrible diseases. What we learn in animal testing will be critical in enabling us to fine tune the process so that we can proceed with clinical trials."

To get the latest news on Halberd's exciting developments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)

For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC

About Halberd Corporation.
Halberd Corporation (OTC PINK:HALB) is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Since its restructuring in April, 2020, Halberd has obtained exclusive worldwide rights to three issued patents and has filed 20 related provisional, PCT, or utility patent applications to enhance its value to its stockholders and to attract the interests of potential development partners.

Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Company cautions our readers that statements and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time the statements are made. These statements may address issues that involve significant risks, uncertainties and associated estimates made by management. Actual results could differ materially from current projections or implied results. Halberd Corporation undertakes no obligation to revise these statements following the date of this news release.

SOURCE: Halberd Corporation